$-0.01 EPS Expected for BiondVax Pharmaceuticals Ltd. (BVXV)

November 10, 2018 - By Mona Holcomb

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Logo

Analysts expect BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) to report $-0.01 EPS on November, 27.They anticipate $0.21 EPS change or 105.00 % from last quarter’s $0.2 EPS. After having $-1.12 EPS previously, BiondVax Pharmaceuticals Ltd.’s analysts see -99.11 % EPS growth. The stock increased 1.62% or $0.09 during the last trading session, reaching $5.52. About 7,741 shares traded or 42.11% up from the average. BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) has declined 13.19% since November 11, 2017 and is downtrending. It has underperformed by 28.81% the S&P500.

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. The company has market cap of $36.08 million. The Company’s product candidate includes M-001, a synthetic peptide protein, which is in Phase II clinical development stage targeting seasonal and pandemic strains of the influenza virus. It currently has negative earnings.

Another recent and important BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) news was published by Prnewswire.com which published an article titled: “BiondVax Receives €8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing …” on October 22, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.